Gisbert J P, Gisbert J-L, Marcos S, Jimenez-Alonso I, Moreno-Otero R, Pajares J M
Gastroenterology Unit, Hospital Universitario de la Princesa and Ciberehd, Universidad Autónoma, Madrid, Spain.
Aliment Pharmacol Ther. 2008 Feb 15;27(4):346-54. doi: 10.1111/j.1365-2036.2007.03573.x. Epub 2007 Nov 12.
Several 'rescue' therapies have been recommended to eradicate Helicobacter pylori, but they still fail in >20% of the cases, and these patients constitute a therapeutic dilemma.
To evaluate the efficacy of different 'rescue' therapies empirically prescribed during 10 years to 500 patients in whom at least one eradication regimen had failed to cure H. pylori infection.
Prospective single-centre study.
Consecutive patients in whom at least one eradication regimen had failed.
Rescue regimens included: (i) quadruple therapy with omeprazole-bismuth-tetracycline-metronidazole; (ii) ranitidine bismuth citrate-tetracycline-metronidazole; (iii) omeprazole-amoxicillin-levofloxacin; and (iv) omeprazole-amoxicillin-rifabutin. Antibiotic susceptibility was unknown (rescue regimens were chosen empirically).
Eradication was defined as a negative (13)C-urea breath test 4-8 weeks after completing therapy.
Five hundred patients were included (76% functional dyspepsia, 24% peptic ulcer). Compliance rates with first-, second- and third-line regimens were 92%, 92%, and 95%, respectively. Adverse effects were reported by 30%, 37%, and 55% of the patients receiving second-, third-, and fourth-line regimens. Overall, H. pylori cure rates with the second-, third-, and fourth-line rescue regimens were 70%, 74%, and 76%, respectively. Cumulative H. pylori eradication rate with four successive treatments was 99.5%.
It is possible to construct an overall treatment strategy to maximize H. pylori eradication, on the basis of administration of four consecutive empirical regimens; thus, performing bacterial culture even after a second or third eradication failure may not be necessary.
已有多种“补救”疗法被推荐用于根除幽门螺杆菌,但仍有超过20%的病例治疗失败,这些患者构成了治疗难题。
评估10年间经验性应用于500例至少一种根除方案未能治愈幽门螺杆菌感染患者的不同“补救”疗法的疗效。
前瞻性单中心研究。
至少一种根除方案失败的连续患者。
补救方案包括:(i)奥美拉唑-铋剂-四环素-甲硝唑四联疗法;(ii)枸橼酸铋雷尼替丁-四环素-甲硝唑;(iii)奥美拉唑-阿莫西林-左氧氟沙星;(iv)奥美拉唑-阿莫西林-利福布汀。抗生素敏感性未知(补救方案为经验性选择)。
根除定义为治疗完成后4 - 8周(13)C -尿素呼气试验阴性。
纳入500例患者(76%为功能性消化不良,24%为消化性溃疡)。一线、二线和三线方案的依从率分别为92%、92%和95%。接受二线、三线和四线方案的患者分别有30%、37%和55%报告有不良反应。总体而言,二线、三线和四线补救方案的幽门螺杆菌治愈率分别为70%、74%和76%。连续四次治疗的累积幽门螺杆菌根除率为99.5%。
基于连续应用四种经验性方案,可以构建一种总体治疗策略以最大限度地提高幽门螺杆菌根除率;因此,即使在第二次或第三次根除失败后进行细菌培养可能也没有必要。